Drug-induced immune hemolytic anemia

Area of Science:

• Hematology
• Immunology
• Pharmacology

Background:

• Drug administration is a significant cause of acquired immune hemolytic anemia, accounting for 16-18% of cases.
• The mechanisms of drug-induced red blood cell sensitization are diverse and depend on the specific drug involved.
• Understanding these mechanisms is crucial for accurate diagnosis and distinguishing drug-induced anemia from other causes.

Purpose of the Study:

• To elucidate the variable pathogenesis of erythrocyte sensitization by drug-related antibodies.
• To explore the relationship between causative drugs, sensitization mechanisms, clinical features, and diagnostic methods.
• To differentiate drug-induced immunohematologic abnormalities from other etiologies.

Main Methods:

• Review of existing literature on drug-induced immune hemolytic anemia.
• Analysis of mechanisms including immune complex formation, drug-coating of red cells, and complement fixation.
• Correlation of drug types with specific sensitization pathways and clinical outcomes.

Main Results:

• Phenacetin and quinidine induce acute intravascular hemolysis via immune complexes and complement fixation.
• Penicillins can cause extravascular hemolysis through IgG anti-drug antibodies coating red cells.
• Cephalosporins may lead to positive direct antiglobulin tests via penicillin-like mechanisms or non-immunologic protein adsorption.

Conclusions:

• Drug-induced immune hemolytic anemia exhibits diverse pathogenetic mechanisms.
• Clinical manifestations and laboratory findings vary based on the drug and sensitization pathway.
• Distinguishing drug-induced anemia requires knowledge of clinical presentations and diagnostic laboratory aids.